Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,288

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

Open access
Wouters, Olivier J, Shadlen, Kenneth C, Salcher-Konrad, Maximilian, Pollard, Andrew J, Larson, Heidi J, Teerawattananon, Yot, Jit, Mark·2021·The Lancet
DOI 10.1016/s0140-6736(21)00306-8
Open this paper in CoChat — free account

Abstract

The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities. In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. Although specific datapoints are subject to change as the pandemic response progresses, the dashboard will continue to provide a useful lens through which to analyse the key issues affecting the use of COVID-19 vaccines. We also present original data from a 32-country survey (n=26 758) on potential acceptance of COVID-19 vaccines, conducted from October to December, 2020. Vaccine acceptance was highest in Vietnam (98%), India (91%), China (91%), Denmark (87%), and South Korea (87%), and lowest in Serbia (38%), Croatia (41%), France (44%), Lebanon (44%), and Paraguay (51%).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)00306-8

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 62

  1. Hanney, 2020, From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?, Health Res Policy Sys, 18, 61, 10.1186/s12961-020-00571-3 · DOI
  2. Davis, 2011, Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline, Vaccine, 29, 9414, 10.1016/j.vaccine.2011.09.128 · DOI
  3. Pronker, 2013, Risk in vaccine research and development quantified, PLoS One, 8, 10.1371/journal.pone.0057755 · DOI · Paper page
  4. Struck, 1996, Vaccine R&D success rates and development times, Nat Biotechnol, 14, 591, 10.1038/nbt0596-591 · DOI
  5. Xue, 2020, Innovation policy and the market for vaccines, J Law Biosci, 7, a026, 10.1093/jlb/lsaa026 · doi:10.1093/jlb/lsaa026
  6. Galkina Cleary, 2018, Contribution of NIH funding to new drug approvals 2010–16, Proc Natl Acad Sci USA, 115, 2329, 10.1073/pnas.1715368115 · DOI · Paper page
  7. Sampat, 2021, The COVID-19 innovation system, Health Aff (Millwood), 10.1377/hlthaff.2020.02097 · DOI
  8. Wang, 2020, Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study, BMJ, 371
  9. Price, 2020, Knowledge transfer for large-scale vaccine manufacturing, Science, 369, 912, 10.1126/science.abc9588 · DOI
  10. Crager, 2018, Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways, Am J Public Health, 108, S414, 10.2105/AJPH.2014.302236r · doi:10.2105/ajph.2014.302236r
  11. Ahonkhai, 2016, Speeding access to vaccines and medicines in low- and middle-income countries: a case for change and a framework for optimized product market authorization, PLoS One, 11, 10.1371/journal.pone.0166515 · DOI
  12. Herlihy, 2016, Current global pricing for human papillomavirus vaccines brings the greatest economic benefits to rich countries, Health Aff (Millwood), 35, 227, 10.1377/hlthaff.2015.1411 · DOI
  13. Hecht, 2010, Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009–31, Lancet, 376, 1254, 10.1016/S0140-6736(10)61255-X · DOI
  14. Hogan, 2005, Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries, BMJ, 331, 1431, 10.1136/bmj.38643.368692.68 · DOI · Paper page
  15. Khamsi, 2020, If a coronavirus vaccine arrives, can the world make enough?, Nature, 580, 578, 10.1038/d41586-020-01063-8 · DOI
  16. Kumar, 2012, US public support for vaccine donation to poorer countries in the 2009 H1N1 pandemic, PLoS One, 7
  17. Fidler, 2010, Negotiating equitable access to influenza vaccines: global health diplomacy and the controversies surrounding avian influenza H5N1 and pandemic influenza H1N1, PLoS Med, 7, 10.1371/journal.pmed.1000247 · doi:10.1371/journal.pmed.1000247
  18. Emanuel, 2020, An ethical framework for global vaccine allocation, Science, 369, 1309, 10.1126/science.abe2803 · DOI · Paper page
  19. Liu, 2020, Multivalue ethical framework for fair global allocation of a COVID-19 vaccine, J Med Ethics, 46, 499, 10.1136/medethics-2020-106516 · DOI
  20. Yamada, 2009, Poverty, wealth, and access to pandemic influenza vaccines, N Engl J Med, 361, 1129, 10.1056/NEJMp0906972 · doi:10.1056/nejmp0906972
  21. Herzog, 2021, COVAX must go beyond proportional allocation of COVID vaccines to ensure fair and equitable access, BMJ, 372
  22. Usher, 2020, COVID-19 vaccines for all?, Lancet, 395, 1822, 10.1016/S0140-6736(20)31354-4 · DOI
  23. 2020, Global governance for COVID-19 vaccines, Lancet, 395
  24. Bollyky, 2020, The equitable distribution of COVID-19 therapeutics and vaccines, JAMA, 323, 2462, 10.1001/jama.2020.6641 · DOI
  25. Yamey, 2020, Ensuring global access to COVID-19 vaccines, Lancet, 395, 1405, 10.1016/S0140-6736(20)30763-7 · DOI · Paper page
  26. So, 2020, Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis, BMJ, 371
  27. Torjesen, 2020, Covid-19: pre-purchasing vaccine-sensible or selfish?, BMJ, 370
  28. Cyranoski, 2020, Arab nations first to approve Chinese COVID vaccine—despite lack of public data, Nature, 588, 548, 10.1038/d41586-020-03563-z · DOI
  29. Cyranoski, 2020, What China's speedy COVID vaccine deployment means for the pandemic, Nature, 586, 343, 10.1038/d41586-020-02807-2 · doi:10.1038/d41586-020-02807-2
  30. Williams, 2020, National routine adult immunization programs among World Health Organization member states: an assessment of health systems to deploy future SARS-CoV-2 vaccines, MedRxiv
  31. Jusu, 2018, Rapid establishment of a cold chain capacity of -60°C or colder for the STRIVE Ebola vaccine trial during the Ebola outbreak in Sierra Leone, J Infect Dis, 217, S48, 10.1093/infdis/jix336 · DOI · Paper page
  32. Trogen, 2020, Adverse consequences of rushing a SARS-CoV-2 vaccine: implications for public trust, JAMA, 323, 2460, 10.1001/jama.2020.8917 · DOI
  33. Schaffer DeRoo, 2020, Planning for a COVID-19 vaccination program, JAMA, 323, 2458, 10.1001/jama.2020.8711 · DOI · Paper page
  34. Lurie, 2020, The development of COVID-19 vaccines, JAMA, 324, 439, 10.1001/jama.2020.12461 · DOI
  35. Gostin, 2020, The dual epidemics of COVID-19 and influenza: vaccine acceptance, coverage, and mandates, JAMA, 324, 335, 10.1001/jama.2020.10802 · DOI
  36. Larson, 2011, Addressing the vaccine confidence gap, Lancet, 378, 526, 10.1016/S0140-6736(11)60678-8 · DOI · Paper page
  37. Karafillakis, 2016, Vaccine hesitancy among healthcare workers in Europe: a qualitative study, Vaccine, 34, 5013, 10.1016/j.vaccine.2016.08.029 · DOI · Paper page
  38. Karafillakis, 2017, The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations, Vaccine, 35, 4840, 10.1016/j.vaccine.2017.07.061 · DOI · Paper page
  39. Larson, 2016, The state of vaccine confidence 2016: global insights through a 67-country survey, EBioMedicine, 12, 295, 10.1016/j.ebiom.2016.08.042 · DOI · Paper page
  40. Peretti-Watel, 2020, A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation, Lancet Infect Dis, 20, 769, 10.1016/S1473-3099(20)30426-6 · DOI · Paper page
  41. Szilagyi, 2021, National trends in the US public's likelihood of getting a COVID-19 vaccine—April 1 to December 8, 2020, JAMA, 325, 396, 10.1001/jama.2020.26419 · DOI · Paper page
  42. Schwarzinger, 2021, COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics, Lancet Public Health, 10.1016/S2468-2667(21)00012-8 · DOI · Paper page
  43. Shah, 2020, Unwavering regulatory safeguards for COVID-19 vaccines, JAMA, 10.1001/jama.2020.15725 · DOI
  44. Ball, 2020, The epic battle against coronavirus misinformation and conspiracy theories, Nature, 581, 371, 10.1038/d41586-020-01452-z · DOI · Paper page
  45. Johnson, 2020, The online competition between pro- and anti-vaccination views, Nature, 582, 230, 10.1038/s41586-020-2281-1 · DOI · Paper page
  46. Burki, 2020, The online anti-vaccine movement in the age of COVID-19, Lancet Digit Health, 2, e504, 10.1016/S2589-7500(20)30227-2 · DOI · Paper page
  47. Ball, 2020, Anti-vaccine movement could undermine efforts to end coronavirus pandemic, researchers warn, Nature, 581, 251, 10.1038/d41586-020-01423-4 · DOI
  48. Dubé, 2015, Strategies intended to address vaccine hesitancy: review of published reviews, Vaccine, 33, 4191, 10.1016/j.vaccine.2015.04.041 · DOI · Paper page
  49. Jarrett, 2015, Strategies for addressing vaccine hesitancy—a systematic review, Vaccine, 33, 4180, 10.1016/j.vaccine.2015.04.040 · DOI · Paper page
  50. Ghinai, 2013, Listening to the rumours: what the northern Nigeria polio vaccine boycott can tell us ten years on, Glob Public Health, 8, 1138, 10.1080/17441692.2013.859720 · DOI
  51. Chandler, 2020, Optimizing safety surveillance for COVID-19 vaccines, Nat Rev Immunol, 20, 451, 10.1038/s41577-020-0372-8 · doi:10.1038/s41577-020-0372-8
  52. Halbert, 2006, Racial differences in trust in health care providers, Arch Intern Med, 166, 896, 10.1001/archinte.166.8.896 · DOI · Paper page
  53. Corbie-Smith, 2002, Distrust, race, and research, Arch Intern Med, 162, 2458, 10.1001/archinte.162.21.2458 · DOI · Paper page
  54. Uscher-Pines, 2011, Racial and ethnic disparities in uptake and location of vaccination for 2009-H1N1 and seasonal influenza, Am J Public Health, 101, 1252, 10.2105/AJPH.2011.300133 · DOI
  55. Wilson, 2018, Rotavirus vaccine coverage and factors associated with uptake using linked data: Ontario, Canada, PLoS One, 13
  56. MacDonald, 2016, Coverage and determinants of uptake for privately funded rotavirus vaccine in a Canadian birth cohort, 2008-2013, Pediatr Infect Dis J, 35, e177, 10.1097/INF.0000000000001125 · doi:10.1097/inf.0000000000001125
  57. Lovie-Toon, 2016, Immunisation timeliness in a cohort of urban Aboriginal and Torres Strait Islander children, BMC Public Health, 16, 10.1186/s12889-016-3825-z · DOI
  58. Murphy, 2020, Inside China's response to COVID, Nature, 588, S49, 10.1038/d41586-020-03361-7 · DOI
  59. Thiagarajan, 2021, Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust, BMJ, 372, n196, 10.1136/bmj.n196 · DOI
  60. Usher, 2021, CEPI criticised for lack of transparency, Lancet, 397, 265, 10.1016/S0140-6736(21)00143-4 · doi:10.1016/s0140-6736(21)00143-4
  61. Berndt, 2007, Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness, Health Econ, 16, 491, 10.1002/hec.1176 · DOI
  62. Baric, 2020, Emergence of a Highly Fit SARS-CoV-2 Variant, N Engl J Med, 383, 2684, 10.1056/NEJMcibr2032888 · DOI

Cited by

See all 1,288

Metadata

Authors
Wouters, O. J., Shadlen, K. C., Salcher-Konrad, M., Pollard, A. J., Larson, H. J., Teerawattananon, Y., & Jit, M.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-03
Volume
397
Issue
10278
Pages
1023-1034
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(21)00306-8
OpenAlex
W3131672727
Cited by
1,288
References
8
FWCI
148.44
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • Engineering and Physical Sciences Research Council (EP/R013756/1)
  • Bill and Melinda Gates Foundation (INV-016832)
  • UK Research and Innovation (MC_PC_19055)
  • Coalition for Epidemic Preparedness Innovations
  • Deutsches Zentrum für Infektionsforschung
  • London School of Hygiene and Tropical Medicine
  • NIHR Oxford Biomedical Research Centre
  • National Institute for Health Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00306-8
The paper
Wouters, O. J., Shadlen, K. C., Salcher-Konrad, M., Pollard, A. J., Larson, H. J., Teerawattananon, Y., & Jit, M. (2021). Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet. https://doi.org/10.1016/s0140-6736(21)00306-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.